Navigation Links
Inimex Announces Appointment of New CEO

BURNABY, BC, Nov. 23 /PRNewswire/ - Inimex Pharmaceuticals, Inc. announced today that it has appointed Michael J. Abrams, Ph.D as its President and CEO.

Abrams brings more than 25 years of drug discovery and development experience to Inimex. He is a co-inventor of the nuclear medicine imaging agent, Cardiolite, and worked from 1984 to 1996 at Johnson Matthey, plc where he was Manager, Biomedical Research Worldwide. In 1996, Abrams led the establishment of AnorMED in Langley, BC and was President and CEO from 1996 to 2006. AnorMED discovered and developed Mozobil, a drug for improving stem cell collection in cancer patients undergoing stem cell transplantation. AnorMED was acquired by Genzyme Corp. for $580M in 2006, and Mozobil was FDA approved in December 2008. Abrams is actively involved in the Vancouver biotech community as a member of public, private and not-for-profit boards.

"We are thrilled that Dr. Abrams has joined the Inimex executive team," said Robert Fildes, Chairman of the Board of Inimex. "His experience and leadership qualities will be a great asset to Inimex as the company makes the transition from a pre-clinical company to one with a drug candidate advancing through clinical development."

Dr. John R. North, who led the early development of Inimex' drug technology, serving as EVP of R&D in 2004 and then President and Chief Executive Officer from 2005 to 2009, will assume a new role as Chief Operating Officer.

"In this era of increasing antibiotic resistance and emerging infectious diseases, new strategies for dealing with these problems are very much in demand. Inimex, with its Innate Defense Regulator technology, is in a great position to address these needs," said Abrams.

    About Inimex Pharmaceuticals

Inimex Pharmaceuticals Inc. is a privately held biopharmaceutical company dedicated to the discovery and development of new medicines based on the selective modulation of the innate immune response. With its first drug candidate, IMX942, having completed Phase 1 clinical studies in healthy volunteers, Inimex' products show promise for the safe and effective treatment of a broad spectrum of serious unmet medical needs in infectious disease and inflammatory disorders.

For more information, please visit

SOURCE Inimex Pharmaceuticals Inc.

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
(Date:11/24/2015)... Cepheid (NASDAQ: CPHD ) today announced ... conference, and invited investors to participate via webcast. ... December 1, 2015 at 11.00 a.m. Eastern Time ... December 1, 2015 at 11.00 a.m. Eastern Time ... York, NY      Tuesday, December 1, 2015 at ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... year and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual ... November 2015, where ISPE hosted the largest number of attendees in more than ...
(Date:11/24/2015)... ... ... This fall, global software solutions leader SAP and AdVenture Capital brought together dozens ... BIG ideas to improve health and wellness in their schools. , Now, the top ... of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, and an ...
(Date:11/24/2015)... 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its ... at 11:00 a.m. Israel time, at the law ... Allon Street, 36 th Floor, Tel Aviv, Israel ... and Izhak Tamir to the Board of Directors; ... directors; , approval of an amendment to certain terms of options ...
Breaking Biology Technology:
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... Oct. 27, 2015 In the present market ... concern for various industry verticals such as banking, healthcare, ... the growing demand for secure & simplified access control ... such as hacking of bank accounts, misuse of users, ... such as PC,s, laptops, and smartphones are expected to ...
(Date:10/26/2015)... 26, 2015 ... adds Biometrics Market Shares, Strategies ... well as Emerging Biometrics Technologies: Global ... its collection of IT and Telecommunications ... --> . ...
Breaking Biology News(10 mins):